« Back
Home /
Tanespimycin

Tanespimycin

Manufacturer	MedChem Express
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Heart & Blood Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	100 mg
Item no.	HY-10211-100mg
Targets	HSP; Autophagy; Mitophagy; Bacterial; Apoptosis; Antibiotic
CASRN	75747-14-7
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	585.69
Clinical_Information	Phase 3
Manufacturers Research_Area	Cancer; Infection
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturers Target	Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy
Isoform	HSP90
Pathway	Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10211-100mg-safety-datasheet.pdf